Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.08 USD | +1.10% | +4.10% | -26.90% |
May. 23 | U.S. FDA advisers back approval for Guardant's cancer test | RE |
May. 21 | Exact Sciences Says Court Allows Patent Lawsuit Against Geneoscopy to Proceed | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The company's enterprise value to sales, at 4.09 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.90% | 9.98B | A- | ||
-16.78% | 2.75B | C | ||
-17.50% | 2.07B | - | B- | |
-24.25% | 1.59B | C+ | ||
+64.58% | 1.43B | B- | ||
+31.92% | 824M | C- | ||
-5.02% | 733M | C+ | ||
-29.59% | 508M | C- | ||
+0.20% | 296M | - | - | |
-28.40% | 158M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EXAS Stock
- Ratings Exact Sciences Corporation